Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Boston IVF Welcomes Reproductive Endocrinologist Dr. Sara Arian to Its Growing Fertility Center in Quincy, Massachusetts


Fertility Specialist, Boston IVF

Sara Arian, MD, MSci

“Each day, I am incredibly motivated by the strength of my patients, who are navigating through one of the most intimate and challenging journeys of their lives.” – Sara Arian, MD, MSci.

Boston IVF, one of the world’s most experienced fertility treatment providers, which has assisted in over 125,000 babies born since 1986 and is known for achieving some of the highest IVF success rates in the country, is pleased to announce the addition of fertility doctor, Sara Arian MD, MSci to its national fertility network and local fertility clinic in Quincy, MA.

Boston IVF’s Quincy Fertility Center offers physician consultations, intrauterine insemination (IUI) treatments, female and male infertility testing, and more to individuals and couples who wish to build a family through assisted reproductive technologies (ART).

Dr. Arian arrives at Boston IVF after having practiced for many years in Houston, Texas, where she served as an Assistant Professor of Reproductive Endocrinology and Infertility at Baylor College of Medicine, and a faculty physician at Texas Children’s Hospital Pavilion for Women. She was named a 2022 Top Fertility Doctor by Houstonia Magazine and received the 2021 and 2022 Texas Rising Star award for fertility care by her peers and independent researchers at SuperDoctors.

She specializes in a comprehensive array of infertility treatments and family building services, including IUI, In Vitro Fertilization (IVF), LGBTQIA+ fertility, single parenting, reproductive surgery (including open and minimally invasive surgeries), uterine fibroid removal, genetic testing, polycystic ovary syndrome (PCOS), endometriosis, complex endocrine and hormonal disorders, and more.

Additionally, she holds a special interest in egg and embryo freezing for both individuals who wish to preserve their fertility for future childbearing and for those who face cancer treatments that may affect their fertility and chance of having a biological child. Chemotherapy and radiation treatments can damage or affect eggs within the ovaries, the ovaries themselves, the pituitary gland, an individual’s hormone levels, and much more.

“Each day, I am incredibly motivated by the strength of my patients, who are navigating through one of the most intimate and challenging journeys of their lives,” said Sara Arian, MD, MSci. “I enjoy listening to, sharing, counseling, guiding, and developing a partnership with my patients throughout their unique journey. My goal is to advocate for each of my patients, empower them with knowledge about their reproductive potential and options, help them to regain control of their reproductive health, and instill confidence in the experience and support that myself and Boston IVF can provide.”

Dr. Arian is a Clinical Instructor in the Department of Obstetrics, Gynecology, and Reproductive Biology at Harvard Medical School and a former Assistant Professor of Reproductive Endocrinology and Infertility at Baylor College of Medicine in Houston. Her goal is to continue to be involved in academic education and training of future physicians, including residents and fellows.

Alongside her role as a reproductive endocrinologist, Dr. Arian is also a passionate scientific investigator and researcher. She holds a master’s degree in Clinical Research from Baylor College of Medicine, has authored numerous medical publications, and received prestigious awards – including the 2019 President’s Presenter’s Award from the Society for Reproductive Investigation (SRI) for her innovative research on reproductive genetics.

“Boston IVF is truly fortunate to add a talented fertility doctor like Dr. Arian to our growing team of reproductive endocrinologists,” said David Stern, CEO of Boston IVF. “She is a passionate advocate for reproductive freedom and an award-winning expert who is dedicated to advancing the science of reproductive medicine through important research and personalized clinical care.”

Dr. Arian completed her Obstetrics, Gynecology, & Reproductive Sciences Residency at the University of Texas Health Science Center in Houston and received her fellowship in Reproductive Endocrinology & Infertility at the Cleveland Clinic and Baylor College of Medicine.

To learn more about Dr. Arian, to receive fertility treatment advice, or to schedule a consultation, visit http://www.bostonivf.com.

ABOUT BOSTON IVF

Boston IVF is one of the largest and most experienced fertility networks in the United States, with more than 125,000 babies born since 1986. Founded as one of the nation’s first private practice IVF centers, the Boston IVF network has grown to include over 30 reproductive endocrinologists across 30 centers throughout Massachusetts, Maine, New Hampshire, Rhode Island, New York, Delaware, Idaho, Indiana, North Carolina, Ohio, and Utah. A renowned innovator of reproductive technologies, advanced protocols, and cutting-edge research, Boston IVF has achieved numerous “firsts” in reproductive care. Its scientific and research arm continues to pave the way for breakthroughs in fertility care and its accredited REI Fellowship Program has graduated numerous reproductive endocrinologists as part of its mission to train the next generation of fertility experts.

Share article on social media or email:

With Bellyy exercise program Diastasis Recti can significantly be improved


Heal abdominal separation & its associated symptoms | Bellyy exercise | diastasisrectiexercise.com

Heal abdominal separation & its associated symptoms | Bellyy exercise | diastasisrectiexercise.com

The Bellyy exercise program is meant to optimize the quality of life of mothers and others who live with abdominal separation (Diastasis Recti) & its associated symptoms. It is medically proven that with Bellyy exercises Diastasis Recti can significantly be improved and just in a couple of weeks.

Heal abdominal separation & its associated symptoms

The health of your abdominal wall is not only a question of aesthetics

The Bellyy exercise program is meant to optimize the quality of life of mothers and others who live with abdominal separation & its associated symptoms. This online exercise regime has 7+1 parts and it was developed for the rehabilitation of the separated abdominal muscle condition. It is medically proven that with daily 10-15 minutes of Bellyy exercises Diastasis Recti can significantly be improved and just in a couple of weeks. As a result of the exercises, 2/3 of the patient’s opened abdominal muscles were closed entirely and the others achieved a reduction in the abdominal volume of a minimum of 4.5 cm and a maximum of 14 cm.

How could we get back to our prenatal shape? Is it even possible?

Genetics plays a key role! It is worth taking a look at both paternal and maternal parents to see how the mothers’ shape changed after giving birth, considering the invested exercise and other factors like diet, lifestyle, etc. We all know women who are lucky to get back in shape 1 month after delivery. Mothers who do not develop DRAM should still exercise regularly to maintain their abdominal muscle condition.

Those who are dissatisfied with their new shape after delivery should be patient. By the end of breastfeeding, hormonal changes that shape the body during pregnancy and delivery will end. This is the perfect time to get a more realistic picture of what the after-delivery body shape will look like. If the weight gain is significant, it’s definitely worth discussing the possibilities and the lifestyle changes needed with a nutrition consultant and a competent trainer.

These professionals can tailor their advice to the needs of each new mom.

Test your ABS | Determine if Diastasis Recti affects you! It only takes 5 minutes to determine the condition of an open abdominal muscle.

Diastasis Recti (DRAM)

Nearly 70% of the population sooner or later will experience open abdominal muscle problems and some of their associated symptoms.

Approximately 75% of new mothers are affected by some form of an open abdominal muscle problem. Older-aged men are also affected by Diastasis Recti (DRAM) caused by weight change and obesity. This is not only an aesthetic problem but also a detriment to the quality of life. The Diastasis Recti (open abdominal muscle) practically means that the rectus abdominal muscles do not close up, a gap remains in between them, and a condition develops that can lead to serious health problems. The neglect of Diastasis Recti can even lead to further complications and subsequent health problems- hernia-, and spine problems. Abdominal muscles have an important role in the optimal sustenance of digestion, venous circulation of lower limbs, and the regulation of blood pressure and lymphatic circulation. A sluggish abdominal muscle can also affect pelvic floor muscle functions.

The condition of the muscles and abdominal wall can be greatly improved by doing the Bellyy exercise program regularly. The exercise program is available online: https://diastasisrectiexercise.com/

Follow Bellyy!

Facebook: https://www.facebook.com/bellyy.io

Instagram: https://www.instagram.com/bellyy.io

Twitter: https://twitter.com/BellyyExercise

YouTube: https://www.youtube.com/channel/UChIo-NIKPxRGEaxGhH2Psbg

Video: https://www.youtube.com/watch?v=n5eGCi_mD4Y

Share article on social media or email:



Abt To Manage Nursing Home Network for Tracking SARS-CoV-2 and Other Infectious Diseases through New CDC Award


“This project will enable CDC to quickly understand the spread of infectious diseases, including COVID-19, in this vulnerable population,” said Dr. Danielle Hunt, vice president of Abt’s Public Health Portfolio.

The Centers for Disease Control and Prevention (CDC) has awarded Abt Associates a three-year contract valued at up to $24 million to establish the Nursing Home Public Health Response Network. The network of geographically dispersed nursing homes will hold pre-positioned research teams so they can conduct rapid-response data collection on SARS-CoV-2 variants and other emerging infectious diseases.

Abt will serve as the Coordinating Center for the network, which will conduct multiple studies. The network includes academic partners and affiliated nursing homes, quality improvement organizations representing most states, and laboratory services. The data will inform infection prevention and control strategies for nursing homes and help accelerate CDC initiatives to address infectious diseases, particularly diseases that cause substantial morbidity and mortality in this population.

“This project will enable CDC to quickly understand the spread of infectious diseases, including COVID-19, in this vulnerable population,” said Dr. Danielle Hunt, vice president of Abt’s Public Health Portfolio. “The data will help to inform protocols to protect residents, their families, and nursing home staff.”

The first year of the contract is valued at $8 million, as is each of two option years. CDC’s Division of Healthcare Quality and Promotion awarded the contract under the Safety and Healthcare Epidemiology Prevention Research Development Program contract vehicle.

About Abt Associates

Abt Associates is a global consulting and research firm that combines data and bold thinking to improve the quality of people’s lives. We partner with clients and communities to advance equity and innovation—from creating scalable digital solutions and combatting infectious disease, to mitigating climate change and evaluating programs for measurable social impact—and more.

http://www.abtassociates.com

Contact: Stan Crock

stan_crock@abtassoc.com

(301) 347-5402

Share article on social media or email:

EnsoData Appoints Dr. Nathaniel Watson as New Chief Medical Officer


Dr. Nathaniel Watson, EnsoData’s new Chief Medical Officer

“In this new role, I’m excited to advance the sleep health care discussion with payors, employers, providers and patients to optimize systems to affordably maximize the populations’ sleep health,” said Dr. Watson.

EnsoData, the healthcare technology company helping clinicians uncover disease while patients sleep, announces the expansion of its leadership roster, adding over 75 years of clinical expertise. EnsoData welcomes Chief Medical Officer (CMO) Dr. Nathaniel Watson, Sales Engineer Kimi Clark, RPSGT, RST, CCSH, FAAST, Sleep Coach Lacey Adams, RPSGT, CCSH, and Regional Sales Manager Jessica Moore, RPSGT to accelerate its mission to make high-quality data analysis more accurate, efficient, and affordable.

With the introduction of Dr. Watson in the new CMO role, EnsoData is strengthening its commitment to advance the state of knowledge on the role of sleep on human health and disease. EnsoData plans to expand both within and beyond the realm of sleep diagnosis through AI research, the improvement in clinical quality of existing products, and the translation of new products from the AI research “lab bench” to the patient bedside.

“With 20+ years in patient care and clinical leadership roles at leading provider organizations, Nate brings exceptional healthcare experience and first-hand physician perspective to EnsoData’s leadership team,” said Chris Fernandez, CEO and Co-Founder of EnsoData. “I’m confident Nate will elevate our ability to continue raising the industry bar for the quality and standard of evidence leveraged to bring new products to market.”

Dr. Watson joins EnsoData as the former President of the American Academy of Sleep Medicine (AASM). With over 20 years of experience in neurology and sleep medicine, he has written over 100 peer-reviewed research publications and has decades of personal experience taking care of patients with sleep disorders. He also has past experience teaching as a Professor at the University of Washington in Seattle and working as the Co-Director of the University of Washington Medicine Sleep Center as well as Director of the Harborview Medical Center Sleep Clinic.

“In this new role, I’m excited to advance the sleep health care discussion with payors, employers, providers and patients to optimize systems to affordably maximize the populations’ sleep health,” said Dr. Watson. “The EnsoData culture of thinking outside the box and imagining how to transform sleep medicine is the perfect avenue for reaching that goal.”

In addition to Dr. Watson, the company hired Clark, Moore, and Adams to build out its clinical team, which includes Andrea Ramberg, MS, RPSGT, CCSH, and Shahnawaz Khan, RPSGT. Clark joins the team as a Sales Engineer, bringing over 15 years of proven experience in growing and leading a health organization in her past role as the Director of Clinical Operations at Medbridge Healthcare. Prior to Moore’s new role as a Regional Sales Manager at EnsoData, she was a Lead Technologist at West Virginia University Health-East Center and has crucial experience in integrating new technologies into existing hospital systems that will help with the adoption and implementation of EnsoData’s technologies. Adams joins EnsoData as a Sleep Coach with over seven years of experience as a Registered Polysomnographic Technologist and Technical Director from St. Vincent’s One Nineteen Health and Wellness Center. Her expertise in diagnostic testing, treatment, and management of sleep apnea and other sleep disorders will allow EnsoData to further educate and support sleep patients in improving their sleep hygiene and quality of sleep.

About EnsoData

EnsoData is a healthcare technology company that uses artificial intelligence to perform complex and time-consuming data interpretation and analysis of waveforms. EnsoData’s FDA cleared sleep study management solution, EnsoSleep, is a complete viewing, scoring, editing and reporting software platform that simplifies and improves the sleep testing, diagnosis and treatment workflow. The simplified workflow saves clinicians time, providing more opportunities to expand patient care, improve outcomes and treat more patients.

Learn more at ensodata.com.

Share article on social media or email:

FYZICAL Therapy & Balance Centers Named Top Franchise for Veterans and Most Innovative Franchise


FYZICAL Therapy & Balance Centers, the country’s fastest-growing physical therapy franchise with more than 480 open centers nationwide, has been recognized by Franchise Business Review as a Top Franchise for Veterans and the Most Innovative Franchise. With streamlined processes and an emphasis on wellness, many former service members find FYZICAL is a perfect fit for their entrepreneurial passions.

“As a veteran, I understand the valuable skills and experiences that are gained during service,” explained Brian Belmont, CEO of FYZICAL. “One of the most crucial aspects of military service is the ability to follow proven processes and commit to a plan. These skills enable veterans to succeed in franchising after retirement.”

As FYZICAL Therapy & Balance Centers has grown, it has built a proven business model that allows dedicated franchise owners to invest, embrace protocols and hit the ground running.

“As someone with military experience, if you give me a regulation, I can implement it!” said Mark Oordt, a FYZICAL franchise owner and retired Air Force Colonel. “In some ways, that’s what franchising is. You buy a proven model, and your goal as the business owner is to implement it well and lead people; that’s exactly what I did in the military.”

The physical therapy brand’s innovative techniques, including a proprietary paradigm to progress patients through their recovery from balance and vestibular disorders, create a more streamlined experience for franchise owners and their rehabilitation teams as they work to execute the strategy provided.

FYZICAL’s franchisees were surveyed on 33 benchmark questions about their experience and satisfaction regarding critical areas of their franchise systems, including leadership, training & support, operations, franchisor/franchisee relations and financial opportunity, and their responses played a crucial role in FYZICAL’s placement on the Franchise Business Review Most Innovative Franchises list.

“Innovation takes a lot more than just having creative ideas and solutions. It also takes execution,” said Eric Stites, founder and CEO of Franchise Business Review. “Each of the companies on our list of the Most Innovative Franchises has developed and implemented products, processes, or services that enable and sustain growth and long-term relevancy.”

In addition to its proven business model and innovative techniques, FYZICAL’s mission often aligns with veterans’ experiences and passions as well. As physical therapists work to support their patients in recovering from surgeries and improving balance, for example, they contribute to the patient’s overall physical ability and wellness. This emphasis on wellness is not foreign to those with military experience.

“Certainly in the military, fitness and wellness are extremely important,” Oordt added. “We’re a community that has a great interest in those things, and it’s great to have a business opportunity that is equally focused on the wellness aspect and keeping people functional.”

To learn more about FYZICAL or to schedule an appointment at a clinic near you, visit fyzical.com.

About FYZICAL Therapy & Balance Centers

Founded in 2012, FYZICAL Therapy & Balance Centers is a physical therapy franchise with more than 480 locations across 45 states. FYZICAL offers a medically based approach to health and wellness and offers comprehensive patient care through unique balance protocols and healthy lifestyle products and services. FYZICAL is a champion of patient choice and direct access, and a leader in the future of health, wellness and preventative care. For more information or to find the nearest location, please visit fyzical.com.

Share article on social media or email:

Farlong Nutraceutical Initiates “Generally Recognized As Safe” (GRAS) Assessment for Plant Extracts, Xiaohongshen and Qingyangshen


Xiaohongshen (Radix Et Rhizonma Rubiae Yunnanensis)

Farlong Nutraceutical initiated the process to earn GRAS status with the U.S. Food & Drug Administration (FDA) for the natural ingredients, Xiaohongshen and Qingyangshen, which are both used to develop the company’s proprietary formula for InnerPure® Colon Detox.

Farlong Nutraceutical, a vertically integrated, plant-based ingredient and supplement company, has initiated the process to earn Generally Recognized As Safe (GRAS) status with the U.S. Food & Drug Administration (FDA) for the natural ingredients, Xiaohongshen (Radix Et Rhizonma Rubiae Yunnanensis) and Qingyangshen (Radix Cynanchi Otopylli).

Xiaohongshen is derived from the dried roots and rhizomes of Rubia yunnanensis Diels. The extract works to nourish and enhance regular blood flow and remove blood stasis to promote tissue regeneration. It is also used to help with infertility; bruises and strains; numbness; joint swelling and pain; rheumatic pain; cough and wheezing; dizziness; headaches; abdominal pain; and insomnia.

Qingyangshen is extracted from the dried roots of Cynanchum otophyllum Schneid, Asclepiadaceae and has been utilized to help with strengthening muscles, bones, the spleen and stomach; treating cold symptoms; relieving spasms; lumbar weakness; muscle and bone pain; loss of appetite; epilepsy, and febrile convulsions.

Both ingredients are used to develop the company’s proprietary formula for InnerPure® Colon Detox, an all-natural blend of eight different herbal extracts. Farlong is currently conducting a 30-day double blind, placebo-controlled safety and efficacy study with 125 healthy human subjects using InnerPure® Colon Detox to determine the effects on healthy bowel movement, weight management and acne. The formula’s many properties include the ability to promote detoxification and healthy, glowing skin; reduce acne, dark spots and pimples; improve circulation and bowel movement; and promote anti-aging. InnerPure® can be a powerful tool for managing weight as it helps with digestion by assisting the body to better absorb nutrients from food, allowing you to eat less and still receive the energy benefits. It also enhances the metabolism which can assist in burning off fat more efficiently, especially during exercise.

Farlong’s ingredient studies:

Farlong is currently conducting a 90-day double blind, randomized, controlled, parallel study to determine the safety and effectiveness of Farlong Lifeflower® Breviscapine on improving long and short-term memory, concentration, and clarity of thinking in healthy individuals. In 2020, the company completed a three-year clinical trial in North America to determine the effects of Ginseng Plus® Panax Notoginseng™ extract, which demonstrated that Farlong NotoGinseng™ (Farlong Ginseng Plus® Panax Notoginseng extract) supplementation was well tolerated and may have a positive influence on reducing the risk of cardiovascular disease by improving blood pressure and HDL-C. The trial results are published in a peer-reviewed medical journal, Current Nutraceuticals Journal by Bentham Science.

About Farlong Nutraceutical:

Farlong is a science-based and vertically integrated functional ingredient and formula provider who has more than 24 years of experience focusing on discovering, developing, and providing safe, effective, and unique medicinal herbs, plant extracts, and formulas with its own GAP (Good Agricultural Practice) certified cultivation base, cGMP (Current Good Manufacturing Practice) certified manufacturing facilities and distribution channels. Combining ancient Oriental medicine and modern technology, Farlong develops its own line of natural supplement brands, while offering contract manufacturing services and ingredients for health and beauty companies to create proprietary formulas and product lines. For more information, visit Farlong.com for supplements and 400+ ingredients, and follow on Facebook, Twitter and Instagram.

Share article on social media or email:



Xtalks Announces its Life Science Webinar Calendar for November 2022


News Image

Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries. Access to all webinars is free, so be sure to register today to save your place! Participate in the discussion and stay relevant in your field!

Visit http://www.xtalks.com to see our upcoming webinars:

BIOMARKERS

November 18- Clinically-Relevant Biomarker Strategies in Drug Development and the Potential of Machine-Learning for Biomarker Assessment

CLINICAL TRIALS

November 2- IRT Transformation for Greater Supply Efficiency

November 2- Care is Critical: Lessons Learned from Clinical Trial Inspections

November 3- Decentralization in Action: What Oncology Trials Look Like Now

November 4- How Sponsors are Accelerating Clinical Trials with Automatic EHR Integration

November 8- The Need for Standardization and CDISC: Insights from The University of Alabama, The University of Utah & CDISC

November 9- Driving Outcomes in Medical Affairs — Leveraging Technology to Identify Successful MSL-KOL Relationships

November 10- Deploying a Patient-First Framework to Accelerate Recruitment & Reduce Overall Trial Timelines

November 11- How Site-Based eSource Benefits Sponsors by Boosting Site Success

November 14- How Early Detection & Diagnostic Products Will Shape the Future of Healthcare

November 16- Radiation Toxicity — Considerations for Implementing Radiation Dose Limits in Radiopharmaceutical Trials

November 16- The Changing Face of Trial Recruitment: Site-Only and Recruitment Provider Options

November 16- eConsent — Driving Successful Adoption

November 17- The Importance of Data Integrity and Accessibility in Successful Clinical Trial Management

November 23- The Value of Patient Co-Creation in Clinical Trial Design

November 29- Scaling DCTs to Drive the Transformation of Clinical Development

November 30- Risk Assessment: Traditional and Novel Approaches to Assess and Manage Risks

DRUG DISCOVERY & DEVELOPMENT

November 7- Applications of Cryopreserved Human Dissociated Tumor Cells (DTCs) for Drug and Diagnostic Development

November 11- Next-Generation Sequencing Applications for Antiviral Drug Development & FDA Guidance for Data Submission

November 15- Emerging Applications for Liquid Biopsy in Drug Development

HEALTHCARE

November 22- Supporting Antimicrobial Stewardship Using Point of Care CRP Testing

November 25- Using Point of Care Testing to Transform Patient Care in General Practice and Primary Care Networks

November 29- FROM-16: Measuring the Hidden Burden of Family Impact of Disease

LABORATORY TECHNOLOGY

November 2- Key Buffer Considerations for AAV Full Capsid Enrichment

November 7- Using Single-Cell DNA Sequencing to Unravel Clonal Heterogeneity & Progression to Richter’s Transformation in CLL

November 9- Detection of COVID-19 Viral RNA in Wastewater as a Simple and Sensitive Method of Outbreak Detection in Large Populations

November 18- Automation of Solid-Phase Aromatic Foldamer Synthesis

MEDICAL DEVICE

November 21- Evaluating Clinical Utility of Medical Devices, Diagnostics & Therapeutics with Conjoint Analysis/Clinical Vignettes

PHARMA MANUFACTURING AND SUPPLY CHAIN

November 11- Meeting the Increasing Manufacturing Demands of the Rapidly Growing Cell and Gene Therapy and Vaccine Markets

November 14- Process Intensification in AAV Gene Therapy

November 29- Constructing a Pharma Development & Manufacturing Project Plan: Steps to Evaluate Risk & Find Efficiencies

November 30- AAV Manufacturing — Overcoming the Challenges of Plasmid DNA

PHARMACEUTICAL

November 3- Quality Control of Vaccines and Other Pharmaceutical Preparations by Total Nitrogen Determination

November 17- Potency Assays for ATMPs — Conception, Development, Validation, Matrixed Approaches and Assay Lifecycle

PHARMACEUTICAL REGULATION

November 28- Creating a Global CMC Dossier to Achieve Operational Readiness

PRECLINICAL

November 8- How can Humanized Mouse Models be Used to Study Cancer & the Development of New Immune-Targeted Therapies?

November 10- Optimizing Preclinical Drug Development through Immune Receptor Sequencing in Mouse Models

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://www.xtalks.com.

Share article on social media or email:

Gateway Genomics Joins Forces with Myriad Genetics to Further the Accessibility of Genetic Information to Consumers


News Image

This partnership is a commitment to offer a comprehensive suite of women’s health testing solutions before, during, and after pregnancy.

Gateway Genomics Joins Forces with Myriad Genetics to Further the Accessibility of Genetic Information to Consumers

With a focus on serving soon-to-be-parents through direct-to-consumer channels and participating medical locations, the company brings a sizeable consumer base and clinical network to Myriad Genetics’ prenatal and women’s health business.

Gateway Genomics, developer of direct-to-consumer genetic tests that give families insight into their future children, announces its acquisition by Myriad Genetics, Inc., a leader in genetic testing and precision medicine. Gateway Genomics’ flagship product, the SneakPeek® Early Gender DNA Test, lets parents know the gender of their baby at 6 weeks into pregnancy with 99% accuracy, the earliest method in the world.

With strong brand loyalty, online reviews and Net Promoter Scores, SneakPeek has over 4 million visitors annually to its website and is available through sneakpeektest.com, online channel partners, and more than 1,850 clinicians. It is the best-selling prenatal DNA test on Amazon and the top searched gender test on Google. Consumers who use SneakPeek now can be further educated on the benefits of other forms of genetic testing offered by Myriad Genetics, including non-invasive prenatal screening, carrier screening and hereditary cancer testing.

In mid-2021, the company introduced SneakPeek Snap ®, an automated way for moms to collect blood samples from the arm, in the comfort of their own home. The Snap blood collection device is an extensible innovation that makes it easy for consumers to collect a sample and expands access to affordable testing at home.

“We’re very excited about this opportunity to bring the expertise of our entire team to Myriad to further extend Myriad’s market reach and serve the large, worldwide consumer and clinical base of both companies,” said Gateway Genomics CEO, Chris Jacob. “This partnership represents more than a simple transaction; it is a commitment to offer a comprehensive suite of women’s health testing solutions before, during, and after pregnancy.”

“Together with Myriad, we will further strengthen our focus on product innovation, quality, ease of use, and excellent customer service,” continued Jacob. “Myriad shares our mission to provide genetic insights through the highest-quality tests and services possible. We see numerous commercial synergy opportunities for the combined companies and believe that by joining forces we will increase accessibility to genetic testing and bring the best of both companies to all of our customers.”

Myriad Genetics acquired Gateway Genomics for an upfront cash purchase price of $67.5 million, subject to customary adjustments, and up to $32.5 million in contingent cash consideration upon the achievement of certain performance-based milestones. Raymond James acted as the exclusive financial advisor and Gunderson Dettmer Stough Villeneuve Franklin & Hachigian LLP served as legal advisor to Gateway Genomics in connection with the transaction.

About Gateway Genomics

Gateway Genomics is a personal genomics company with the mission to develop leading-edge genetic tests that give families a new level of understanding about their future children. Since inception, more than 750,000 SneakPeek Early Gender DNA tests have been provided to help new parents bond with their babies, make plans, and connect with friends and family around them. Located in La Jolla, CA, Gateway Genomics has been recognized as an Inc 5000 Fastest Growing Company for four consecutive years.

About Myriad Genetics

Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. Fast Company named Myriad among the World’s Most Innovative Companies for 2022.

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements that the combination will further strengthen Gateway’s strong focus on product innovation, quality, ease of use and excellent customer service, the combination may provide commercial synergy opportunities, and joining forces will increase accessibility of genetic testing to customers. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated.

Share article on social media or email:

American Childhood Cancer Organization (ACCO) is Now Working with CardFunder to Expand Fundraising Efforts


With the help of CardFunder, ACCO is accelerating fundraising efforts

With the help of CardFunder, ACCO is accelerating fundraising efforts


“We are honored to support ACCO’s mission to be the voice of childhood and adolescent cancer,” said Russ Howard, CEO at CardFunder.

The American Childhood Cancer Organization is working to bring more accessible ways to fundraise to our community and has recently started working with CardFunder, a new fundraising platform. CardFunder, allows nonprofits to turn unwanted gift cards into fundraising dollars. Recently, CardFunder launched its online giving platform and Mobile App, which makes fundraising even easier—and donating even more convenient. Donors can give new or partially used gift cards directly through the American Childhood Cancer Organization online campaign page or via Mobile APP powered by CardFunder.

This free tool allows donors to contribute from anywhere in the U.S., making it a game-changer for nonprofit fundraising. “We’re always looking for a new and innovative way to fundraise for our community,” said Blair Scroggs, Public Relations Coordinator at ACCO. Organizations can easily hold a virtual or hybrid fundraiser that solicits gift card donations from supporters across the nation.

“We are honored to support ACCO’s mission to be the voice of childhood and adolescent cancer,” said Russ Howard, CEO at CardFunder. By giving nonprofits an innovative new avenue for fundraising, CardFunder allows them to tap into the billions of unused gift card dollars. Americans have $21 billion in unused gift card funds, averaging $175 per person. Much of that amount will go to waste unless we pursue innovative ways of tapping into those funds. Many people forget to spend their gift card money or didn’t want it to begin with.

Why let these unwanted funds go to waste? With the help of CardFunder, ACCO can set up a fundraiser in minutes. Then, they share their link on their social networks, posting it on Instagram, Facebook, and Twitter. They also receive a QR code and URL-sharing link. Donors scan their gift cards and enter the numbers, following a few simple prompts.

“We’re really excited to see where this collaboration will take us,” said Scroggs.

Interested in getting involved with ACCO and Cardfunder? Click here: https://cardfunder.com/4ro3l-american-childhood-cancer-organization

About CardFunder

CardFunder powers fundraising efforts by enabling organizations to accept unwanted gift cards and monetizing the cards into cash donations. Serving schools, churches, nonprofits, and other groups, CardFunder provides all the tools needed to run a gift card campaign easily. Through these efforts, CardFunder helps local groups and large nonprofits tap into the more than $20B in unspent gift cards.

About ACCO

The American Childhood Cancer Organization was founded in 1970 by parents of children diagnosed with cancer. It is dedicated to making childhood cancer a national health priority through shaping policy, expanding research, raising awareness, and providing educational resources and innovative comfort programs to children with cancer and their families. Please visit http://www.acco.org/donate

Contact Info

CardFunder

Russ Howard

Founder / CEO

russ@cardfunder.com

ACCO:

Blair L. Scroggs

Public Relations Coordinator

bscroggs@acco.org

Share article on social media or email:

American Gene Technologies® Chief Medical Officer Honored by UCSF Endowment for HIV Dermatology and LGBTQ Health Research


News Image

This endowment is a testament to the hard work my colleagues and I accomplished in the 1980s during the HIV/AIDS epidemic. I’m both flattered and humbled to have my name honored with a scholarship that will better the lives of men and women across the globe. -Dr. Conant, AGT™ Chief Medical Officer

American Gene Technologies®, a clinical-stage biotechnology company based in Rockville, Maryland, congratulates Dr. Marcus Conant and the University of California San Francisco (UCSF) Medical Center’s Department of Dermatology for establishing The Marcus Conant, MD, Endowment for HIV Dermatology and LGBTQ Health.

Dr. Conant is American Gene Technologies’ Chief Medical Officer and UCSF’s clinical professor emeritus of dermatology. The endowment named in his honor aims to provide mentorship and support to researchers in HIV-related skin disease and LGBTQ health. Not only will it supply increased funding for researchers early on in their careers, but it will also enable UCSF to remain competitive in recruiting the best and brightest students, residents, and fellows — all with the goal of advancing HIV treatment and LGBTQ health.

“This endowment is a testament to the hard work my colleagues and I accomplished in the 1980s during the HIV/AIDS epidemic,” said Dr. Conant. “I’m both flattered and humbled to have my name honored with a scholarship that will better the lives of men and women across the globe.”

A pioneer in HIV research and treatment, Dr. Conant was one of the first physicians to diagnose HIV in San Francisco. He then took the lead in forming the Kaposi’s Sarcoma Research & Education Foundation, now known as the San Francisco AIDS Foundation, in 1982. In his current role as American Gene Technologies Chief Medical Officer, Dr. Conant continues the fight against HIV with revolutionary work in gene therapy.

“We’re proud to be continuing the work that Dr. Conant was a part of starting so many years ago and to have his guidance in our efforts to develop new cutting-edge gene therapies for HIV,” said Jeff Galvin, CEO and founder of American Gene Technologies. “Thanks to Dr. Conant’s care, leadership, and dedication to helping people diagnosed with HIV in the ’80s and ’90s, many people received important medical attention and empathy at a time when HIV was characterized by misunderstanding, stigma, and neglect. His commitment helped find the first effective treatments that prevented AIDS and restored hope to millions. This scholarship is a fitting legacy to his life-long commitment to fighting HIV and AIDS, and ensures that there will be much more progress to come.”

About American Gene Technologies

American Gene Technologies is a gene therapy company with a proprietary gene-delivery platform for rapid development of gene therapies to cure infectious diseases, cancers, and inherited disorders. Its mission is to transform people’s lives through genetic medicines that rid the body of disease. American Gene Technologies has been granted numerous patents for the technology used to make AGT103-T and for its unique immuno-oncology approach to stimulate gamma-delta (γδ) T cells to destroy a variety of solid tumors. The company has developed a synthetic gene for treating Phenylketonuria (PKU), a debilitating inherited disease. The company’s treatment for PKU has been granted Orphan Drug Designation by the Food and Drug Administration (FDA), and it is expected to reach the clinic in 2023.

Share article on social media or email: